Charles Schwab Investment Management Inc Coherus Bio Sciences, Inc. Transaction History
Charles Schwab Investment Management Inc
- $515 Billion
- Q3 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Coherus Bio Sciences, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 964,327 shares of CHRS stock, worth $1.47 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
964,327
Previous 848,110
13.7%
Holding current value
$1.47 Million
Previous $1.47 Million
31.7%
% of portfolio
0.0%
Previous 0.0%
Shares
29 transactions
Others Institutions Holding CHRS
# of Institutions
135Shares Held
77.9MCall Options Held
40.7KPut Options Held
50.1K-
Black Rock Inc. New York, NY11.8MShares$17.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.3MShares$17.2 Million0.0% of portfolio
-
Rubric Capital Management LP New York, NY10.4MShares$15.8 Million0.3% of portfolio
-
Kohlberg Kravis Roberts & Co. L.P. New York, NY3.04MShares$4.61 Million0.18% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.86MShares$4.34 Million0.0% of portfolio
About Coherus BioSciences, Inc.
- Ticker CHRS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,724,600
- Market Cap $118M
- Description
- Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...